NICE TA Adherence Checklist 2018/2019 ELHE

NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Date of Technology appraisal (TA) Time to Date of TA Release with this medical condition, as indicated by local local (hyperlinked) Yes N/A implement NICE decision due decision days (90 days) made

TA508 – Autologous 7th March 2018 Evidence-based recommendations on Y 05/06/2018 18/04/2018 42 chondrocyte implantation autologous chondrocyte implantation using using chondrosphere (Spherox) chondrosphere for ttreating symptomatic for treating symptomatic articular cartilage defects of the knee. articular cartilage defects of the knee TA509 pertuzumab with 7th March 2018 Evidence-based recommendations on Y 05/06/2018 18/04/2018 42 trastuzumab and docetaxel for pertuzumab for treating HER2-positive, treating HER2-positive breast locally recurrent or metastatic (secondary) cancer breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before. NHSE Cancer Drug Fund TA510 – Daratumumab 14th March 2018 Evidence-based recommendations on Y 12/06/2018 18/04/2018 35 monotherapy for treating Daratumumab for relapsed or refractory relapsed and refractory multiple myeloma in adults. multiple myeloma NHSE Cancer Drug Fund TA511 – Brodalumab for 21st March 2018 Evidence-based recommendations on Y 19/06/2018 18/04/2018 28 treating moderate to severe brodalumab for treating moderate to severe plaque psoriasis plaque psoriasis in adults. CCG commissioned (Blue Teq Form) TA512 – Tivozanib for treating 21st March 2018 Evidence-based recommendations on Y 29/06/2018 18/04/2018 28 advanced renal cell carcinoma tivozanib for treating advanced renal cell carcinoma in adults. NHSE Commissioned TA513 – Obinutuzumab for 21st March 2018 Evidence-based recommendations on Y 29/06/2018 18/04/2018 28 untreated advanced follicular obinutuzumab for untreated advanced lymphoma follicular lymphoma in adults. NHSE Commissioned TA514 – Regorafenib for 21st March 2018 Evidence-based recommendations on N/A 29/06/2018 18/04/2018 28 previously treated advanced regorafenib for previously treated advanced hepatocellular carcinoma hepatocellular carcinoma in adults. (Not recommended) TA515 – Eribulin for treating 28th March 2018 Evidence-based recommendations on N/A 06/05/2018 18/04/2018 21 locally advanced or metastatic eribulin for treating locally advanced or breast cancer after 1 metastatic (secondary) breast cancer in chemotherapy regimen adults who have had only 1 course of chemotherapy. (Not recommended) TA516 – Cabozantinib for 28th March 2018 Evidence-based recommendations on Y 06/05/2018 18/04/2018 21 treating medullary thyroid cabozantinib for treating medullary thyroid cancer cancer in adults. NHSE Cancer Drug Fund TA517 – Avelumab for treating 11th April 2018 Evidence-based recommendations on Y 10/07/2018 16/05/2018 35 metastatic Merkel cell avelumab (Bavencio) for treating metastatic carcinoma, only if they have (secondary) Merkel cell carcinoma in adults. had 1 or more lines of NHSE Cancer Drug Fund chemotherapy for metastatic disease. TA518 – Tocilizumab for 18th April 2018 Evidence-based recommendations on Y 17/07/2018 16/05/2018 28 treating giant cell arteritis. tocilizumab (RoActemra) for treating giant cell arteritis in adults. NHSE Commissioned TA519 – Pembrolizumab for 25th April 2018 Evidence-based recommendations on Y 24/07/2018 16/05/2018 21 treating locally advanced or pembrolizumab (Keytruda) for previously metastatic urothelial treated locally advanced or metastatic carcinoma after platinum- urothelial carcinoma in adults. containing chemotherapy NHSE Cancer Drug Fund TA520 – Atezolizumab for 16th May 2018 Evidence-based recommendations on Y 14/08/2018 20/06/2018 35 treating locally advanced or atezolizumab (Tecentriq) for locally metastatic non-small-cell lung advanced or metastatic non-small-cell lung cancer after chemotherapy cancer after chemotherapy in adults. NHSE Commissioned TA521 – Guselkumab for 13th June 2018 Evidence-based recommendations on Y 11/09/2018 20/06/2018 7 treating moderate to severe guselkumab (Tremfya) for treating plaque psoriasis in adults moderate to severe plaque psoriasis in adults. NHSE Commissioned

NICE TA Adherence checklist 2018/2019 ELHE NICE Technology Appraisals (medicines): Formulary Adherence 2018/2019 This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

TA525 – Atezolizumab for 13th June 2018 Evidence-based recommendations on Y 11/09/2018 20/06/2018 7 treating locally advanced or Atezolizumab (Tecentriq) for previously metastatic urothelial treated locally advanced or metastatic carcinoma after platinum- urothelial carcinoma in adults. (there is a containing chemotherapy. separate guidance for people with untreated disease who cannot have cisplatin-based chemotherapy) NHSE Commissioned TA522 – Pembrolizumab for 13th June 1028 Evidence-based recommendations on Y 11/09/2018 18/07/2018 35 untreated PD0L1 –positive pembrolizumab (Keytruda) for untreated locally advanced or metastatic PD-L1-positive locally advanced or urotelial cancer when cisplatin metastatic urothelial carcinoma in adults. is unsuitable NHSE Cancer Drug Fund TA523 – Midostaurin for 13th June 2018 Evidence-based recommendations on Y 11/09/2018 18/07/2018 35 untreated acute myeloid midostaurin (Rydapt) for untreated FLT3- leukaemia mutation-positive acute myeloid leukaemia in adults. NHSE Commissioned TA524 – Brentuximab vedotin 13th June 2018 Evidence-based recommendations on Y 11/09/2018 18/07/2018 35 for treating CD30-positive brentuximab vedotin (Adcetris) for treating Hodgkin lymphoma CD30-positive Hodgkin lymphoma in adults. This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446. NHSE Cancer Drug Fund TA526 – Arsenic trioxide for 13th June 2018 Evidence-based recommendations on Y 11/09/2018 18/07/2018 35 treating acute promyelocytic arsenic trioxide (Trisenox) for treating acute leukaemia promyelocytic leukaemia in adults. NHSE Commissioned TA527 – Beta interferons and 27th June 2018 Evidence-based recommendations on beta Y 25/09/2018 18/07/2018 21 glatiramer acetate for treating interferons (Avonex, Betaferon, Extavia, Multiple Sclerosis Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults. NHSE Commissioned TA217 – Donepezil, 20th June 2018 Evidence-based recommendations on Y 18/09/2018 18/07/2018 28 galantamine, rivastigmine and updated donepezil (Aricept), galantamine (Reminyl), memantine for the treatment rivastigmine (Exelon) and memantine of Alzheimer’s disease (Ebixa) for treating Alzheimer's disease in adults. CCG Commissioned TA528 – Niraparib for 4th July 2018 Evidence-based recommendations on Y 2/10/2018 19/09/2018 77 maintenance treatment of niraparib (Zejula) for treating relapsed, relapsed,platinum-sensitive platinum-sensitive high-grade serous ovarian, fallopian tube epithelial ovarian, fallopian tube or primary peritoneal cancer peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults. NHSE Cancer Drug Fund TA529 – Crizotinib for treating 4th July 2018 Evidence-based recommendations on Y 2/10/2018 19/09/2018 77 ROS1-positive advanced non- crizotinib (Xalkori) for treating ROS1-positive small-cell lung cancer advanced non-small-cell lung cancer in adults. NHSE Cancer Drug Fund TA530 – Nivolumab for treating 4th July 2018 Evidence-based recommendations on N/A 2/10/2018 19/09/2018 77 locally advanced unresectable nivolumab (Opdivo) for treating locally or metastatic urothelial cancer advanced unresectable or metastatic after platinum-containing urothelial carcinoma in adults who have had chemotherapy platinum-containing chemotherapy. (Not recommended) TA531 – Pembrolizumab for 18th July 2018 Evidence-based recommendations on Y 16/10/2018 19/09/2018 63 untreated PD-L1-positive pembrolizumab (Keytruda) for untreated metastatic non-small-cell lung PD-L1-positive metastatic non-small-cell cancer lung cancer in adults. NHSE Commissioned

TA532 – Cenegermin for 18th july 2018 Evidence-based recommendations on N/A 16/10/2018 19/09/2018 63 treating neurotrophic keratitis cenegermin (Oxervate) for treating neurotrophic keratitis in adults. (Not recommended) TA533 – Ocrelizumab for 18th July 2018 Evidence-based recommendations on Y 16/10/2018 19/09/2018 63 treating relapsing-remitting ocrelizumab (Ocrevus) for treating multiple sclerosis relapsing–remitting multiple sclerosis in adults. NHSE Commissioned TA522 – Pembrolizumab for 13th June 2018 Evidence-based recommendations on Y 22/10/2018 19/09/2018 57 untreated PD-L1 –positive (updated 24th July pembrolizumab (Keytruda) for untreated locally advanced or metastatic 2018 PD-L1-positive locally advanced or urothelial cancer when cisplatin metastatic urothelial carcinoma in adults. is unsuitable July 2018: The European Medicines Agency restricted the use of pembrolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. NHSE Cancer Drug Fund TA492 – Atezolizumab for 6th December Evidence-based recommendations on Y 10/10/2018 19/09/2018 69 untreated PD-L1-positive locally 2018 (updated atezolizumab (Tecentriq) for untreated PD- advanced or metastatic 12th July 2018) L1-positive locally advanced or metastatic urothelial cancer when cisplatin urothelial carcinoma in adults. is unsuitable July 2018: The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. NHSE Commissioned TA534 – Dupilumab for treating 1st August 2018 Evidence-based recommendations on Y 30/10/2018 19/09/2018 49 moderate to severe atopic dupilumab (Dupixent) for treating moderate dermatitis to severe atopic dermatitis in adults CCG commissioned (Blue Teq Form) TA535 – Lenvatinib and 8th August 2018 Evidence-based recommendations on Y 6/11/2018 19/09/2018 42 sorafenib for treating lenvatinib (Lenvima) and sorafenib differentiated thyroid cancer (Nexavar) for progressive, locally advanced after radioactive iodine or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. NHSE Commissioned TA536 – Alectinib for untreated 8th August 2018 Evidence-based recommendations on Y 6/11/2018 19/09/2018 42 ALK-positive advanced non- alectinib (Alecensa) for untreated anaplastic small-cell lung cancer lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults. NHSE Commissioned TA537 – Ixekizumab for treating 8th August 2018 Evidence-based recommendations on y 6/11/2018 19/09/2018 42 active psoriatic arthritis after ixekizumab (Taltz) for treating active inadequate response to psoriatic arthritis in adults. DMARDs CCG commissioned TA538 – Dinutuximab beta for 22nd August 2018 Evidence-based recommendations on Y 20/11/2018 19/09/2018 28 teating neuroblastoma dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over. NHSE Commissioned TA539 – Lutetium oxodotreotide 29th August 2018 Evidence-based recommendations on Y 27/11/2018 19/09/2018 21 for treating unrescetable or lutetium (177Lu) oxodotreotide (Lutathera) metastatic neuroendocrine for treating unresectable or metastatic tumours neuroendocrine tumours in adults. NHSE Commissioned TA540 – Pembrolizumab for 3rd September Evidence-based receommendations on N/A 3/12/2018 17/10/2018 45 treating relapsed or refractory 2018 pembrolizumab (Keytruda) for treating classical Hodgkin lymphoma relapsed or refractory classical Hodgkin lymphoma in adults. (not recommended in adults who have had autologous stem cell transplant & brentuximab vedotin)

TA540 – Pembrolizumab for 3rd September Evidence-based recommendations on Y 3/12/2018 17/10/2018 45 treating relapsed or refractory 2018 pembrolizumab (Keytruda) for treating classical Hodgkin lymphoma relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant. Cancer Drugs Fund TA541- Inotuzumab ozogamicin 19th September Evidence-based recommendations on Y 18/12/2018 17/10/2018 28 for treating relapsed or 2018 inotuzumab ozogamicin (Besponsa) for refractory B-cell acute relapsed or refractory CD22-positive B-cell lymphoblastic leukaemia precursor acute lymphoblastic leukaemia in adults. NHSE Commissioned TA542 – Cabozantinib for 3rd October 2018 Evidence-based recommendations on Y 01/01/2019 21/11/2018 49 untreated advanced renal cell cabozantinib (Cabometyx) for untreated carcinoma advanced renal cell carcinoma in adults. NHSE Commissioned TA543 – Tofacitinib for treating 3rd October 2018 Evidence-based recommendations on Y 01/01/2019 21/11/2018 49 active psoriatic arthritis after tofacitinib (Xeljanz) for treating active inadequate response to psoriatic arthritis in adults after inadequate DMARDs response to DMARDs. CCG Commissioned – Blueteq form TA544 – Dabrefenib with 17th October 2018 Evidence-based recommendations on Y 15/01/2019 21/11/2108 35 trametinib for adjuvant dabrafenib (Tafinlar) with trametinib treatment of resected BRAF (Mekinist) for resected stage III, BRAF V600 V600 mutation-positive mutation-positive melanoma in adults. melanoma NHS England Commissioned TA293 – Eltrombopag for 24th July 2013 Evidence-based recommendations on Y 25/01/2019 21/11/2018 26 treating chronic immune Last updated 26th eltrombopag (Revolade) for treating chronic (idiopathic) thrombocytopenic October 2018 immune (idiopathic) thrombocytopenic prupura purpura in adults.This guidance updates and replaces NICE technology appraisal guidance on eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205). CCG Commissioned – Blueteq form TA221 – Romiplostin for the 25th April 2011 – Evidence-based recommendations on Y 25/01/2019 21/11/2018 26 treatment of chronic immune Last updated 26th romiplostim (Nplate) for treating chronic (idiopathic) thrombocytopenic Octobr 2018 immune (idiopathic) thrombocytopenic purpura purpura in adults. CCG Commissioned – Blueteq form TA545 – Gemtuzumab 14th November Evidence-based recommendations on Y 12/02/2019 19/12/2018 35 ozogamicin for untreated acute 2018 gemtuzumab ozogamicin (Mylotarg) for myeloid leukaemia untreated acute myeloid leukaemia in people aged 15 years and over. NHS England Commissioned TA546 – Padeliporfin for 21st November Evidence-based recommendations on N/A 19/02/2019 19/12/2018 28 untreated localised prostate 2018 padeliporfin (Tookad) for untreated, cancer unilateral, low-risk prostate cancer in adults. (Not recommended) TA547 – Tofacitinib for 28th November Evidence-based recommendations on Y 26/02/2019 19/12/2018 21 moderately to severely active 2018 tofacitinib (Xeljanz) for previously treated ulcerative colitis moderately to severely active ylcerative colitis in adults. CCG Commissioned – Blueteq form

TA548 Decitabine for untreated N/A-appraisal NICE is unable to make a recommendation N/A N/A N/A N/A acute myeloid leukaemia terninated about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was received from Janssen. TA549 – denosumab for N/A-appraisal NICE is unable to make a recommendation N/A N/A N/A N/A preventing skeletal-related terninated about the use in the NHS of denosumab for events in multiple myeloma preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen. TA550 - Vandetanib medullary 12th December Evidence-based recommendations on N/A 29/01/2019 16/01/2019 35 thyroid cancer 2018 vandetanib (Caprelsa) for treating medullary thyroid cancer in adults. (Not recommended) TA551 –Lenvatinib for untreated 19th December Evidence-based recommendations on Y 05/02/2019 16/01/2019 28 advanced hepatocellular 2018 lenvatinib (Lenvima) for untreated advanced carcinoma hepatocellular carcinoma in adults. NHS England Commissioned TA552 – Liposomal cytarabine- 19th December Evidence-based recommendations on Y 05/02/2019 16/01/2019 28 daunorubicin for untreated 2018 liposomal cytarabine–daunorubicin (Vyxeos) acute myeloid leukaemia for untreated acute myeloid leukaemia in adults. Cancer Drugs Fund TA553 – Pembrolizumab for 19th December Evidence-based recommendations on Y 05/02/2019 16/01/2019 28 adjuvant treatment of resected 2018 pembrolizumab (Keytruda) for adjuvant melanoma with high risk of treatment of stage III melanoma with lymph recurrence node involvement in adults. Cancer Drugs Fund TA554 – Tisagenlecleucel for 21ST December Evidence-based recommendations on Y 07/01/2019 16/01/2018 26 treating relapsed or refractory 2018 tisagenlecleucel therapy (Kymriah) for B-cell acute lymphoblastic treating relapsed or refractory B-cell acute leukaemia in people aged up to lymphoblastic leukaemia in people aged up 25 years to 25 years. Cancer Drugs Fund TA555 – Regorafenib for 9th January 2019 Evidence-based recommendations on Y 05/03/2019 20/02/2019 42 previously treated advanced regorafenib (Stivarga) for treating advanced heptocellular carcinoma hepatocellular carcinoma in adults who have had sorafenib. NHS England Commissioned TA556 – Darvadstrocel for 9th January 2019 Evidence-based recommendations on N/A 05/03/2019 20/02/2019 42 treating complex perianal darvadstrocel (Alofisel) for previously fistulas in Crohns disease treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease. (Not recommended) TA557 – Pembrolizumab with 10th January 2019 Evidence-based recommendations on Y 06/03/2019 20/02/2019 41 pemetrexed and platinum pembrolizumab (Keytruda) with pemetrexed chemotherapy for untreated, and platinum chemotherapy for untreated, metastatic, non-squamous, non- metastatic, non-squamous non-small-cell small-cell-lung cancer lung cancer in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. Cancer Drugs Fund TA558 – Nivolumab for adjuvant 23rd January 2019 Evidence-based recommendations on Y 19/03/2019 20/02/2019 28 treatment of completely nivolumab (Opdivo) for the adjuvant resected melanoma with lymph treatment of completely resected node involvement or metastatic melanoma in adults with lymph node disease involvement or metastatic disease. Cancer Drugs Fund

Adherence of local formulary to NICE Availability of medicine for NHS patients Date of Date of Technology appraisal (TA) Date of TA Release with this medical condition, as indicated by local local Time to (hyperlinked) Yes N/A NICE decision due decision implement days (90 days) made

TA559 – Axicabtagene 23rd January 2019 Evidence-based recommendations on Y 19/03/2019 20/02/2019 28 ciloleucel for treating diffuse axicabtagene ciloleucel therapy (Yescarta) large B-cell lymphoma and for treating diffuse large B-cell lymphoma primary mediastinal large B-cell and primary mediastinal B-cell lymphoma lymphoma after 2 or more in adults after 2 or more systemic systemic therapies therapies. Cancer Drugs Fund TA560 – Bevacizumab with 20th February NICE is unable to make a recommendation N/A N/A N/A 20/03/2019 N/A carboplatin, gemcitabine and 2019 about the use in the NHS of bevacizumab paclitaxel for treating the first with carboplatin, gemcitabine and occurrence of platinum- paclitaxel for treating the first recurrence of sensitive advanced ovarian platinum-sensitive advanced ovarian cancer cancer (terminated appraisal) because no evidence submission was received from Roche. TA561 – Venetoclax with 27th February Evidence-based recommendations on Y 28/05/2019 20/03/2019 21 rituximab for previously 2019 venetoclax (Venclyxto) with rituximab for treated chronic lymphocytic previously treated chronic lymphocytic leukaemia leukaemia in adults. Cancer Drugs Fund TA562 – Enocorafenix with 27th February Evidence-based recommendations on Y 28/05/2019 20/03/2019 21 binimetinib for unresectable or 2019 encorafenib (Braftovi) with binimetinib metastatic BRAF V600 (Mektovi) for treating unresectable or mutation-positive melanoma metastatic BRAF V600 mutation-positive melanoma in adults. Cancer Drugs Fund TA563 – Abemaciclib with an 27th February Evidence-based recommendations on Y 28/05/2019 20/03/2019 21 aromatase inhibitor for 2019 abemaciclib (Verzenios) for treating locally previously untreated, hormone- advanced or metastatic, hormone receptor- receptor-positive, HER2- positive, human epidermal growth factor negative. Locally advanced receptor 2 (HER2)-negative breast cancer in metastatic breast cancer adults who have not had endocrine-based therapy before. Cancer Drugs Fund TA564 – Dabrafenib with 27th February NICE is unable to make a recommendation N/A N/A N/A 20/03/2019 N/A trametinib for treating 2019 about the use in the NHS of dabrafenib with advanced metastatic BRAF trametinib for treating advanced V600E mutation-positive non- metastatic BRAF V600E mutation-positive small-cell lung cancer non-small-cell lung cancer because no (terminated appraisal) evidence submission was received from Novartis.

Total 51 12 % % Average “Yes” “No” implementation time (days) Adherence statistics for 2018 - 2019 81 19 35

NICE TA Adherence checklist 2018/2019 ELHE